Is the Ramsay Health Care share price a buy?

The Ramsay Health Care Limited (ASX: RHC) share price has just recovered from hitting its lowest level in four years – is it a buy?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

The Ramsay Health Care Limited (ASX: RHC) share price has just recovered from hitting its lowest level in four years. After reaching an all-time high of $81.31 in September 2016, the share price (and Ramsay shareholders) have been suffering ever since. Ramsay did not come out of the recent correction unscathed, with the sell-off dragging the share price to a four-year low of $52.92 in October. It has since bounced back slightly and at the time of writing, is trading around the $58 mark.

Australia's ageing population and ever-rising demand for medical services bode well for the healthcare sector, which has been one of the strongest performers on the ASX over the past decade. Stocks such as CSL Limited (ASX: CSL) and NIB Holdings Limited (ASX: NHF) have generated stellar returns for investors during this time.

Ramsay is Australia's largest private hospital operator, with over 223 hospitals and more than 60,000 staff across several countries, with a strong and expanding presence in Europe. Ramsay has historically enjoyed strong returns on invested capital due to its ownership and management of flagship private hospitals in Australia, resulting in a reputation for high-quality care. The company's scale also enables them to negotiate very effectively with private health insurers, which gives it enormous pricing power. This has enabled Ramsay to establish a significant cost advantage, which has underpinned its successful expansion both in Australia and overseas.

So, what has gone wrong?

Ramsay is facing some difficult structural problems going into 2019. Analysts are expecting core EPS growth of only 2% for the financial year, mainly due to some recent acquisitions that are not yet bearing fruit. Furthermore, declining private health insurance memberships and high out-of-pocket hospital costs are pushing more patients into the public health system, and out of Ramsay's private hospitals, placing pressure on earnings.

However, Ramsay remains confident of its acquisitions and is planning on expanding their business into more areas into the future.

Foolish takeaway

Although Ramsay is facing some short-term headwinds, I believe the demographics of the healthcare sector, both in Australia and around the globe, provide a significant tailwind for the company. I believe Ramsay's effective management team and expansion strategy make Ramsay Health Care a great addition for any long-term investor.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »